OA10049A - Benzanilide derivatives - Google Patents

Benzanilide derivatives Download PDF

Info

Publication number
OA10049A
OA10049A OA60277A OA60277A OA10049A OA 10049 A OA10049 A OA 10049A OA 60277 A OA60277 A OA 60277A OA 60277 A OA60277 A OA 60277A OA 10049 A OA10049 A OA 10049A
Authority
OA
OAPI
Prior art keywords
methyl
group
compound
phenyl
piperazinyl
Prior art date
Application number
OA60277A
Other languages
English (en)
Inventor
Oxford Alexander William
Mitchell William Leonard
Clitherow John Watson
Carter Malcolm
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB919119931A external-priority patent/GB9119931D0/en
Priority claimed from GB929205338A external-priority patent/GB9205338D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of OA10049A publication Critical patent/OA10049A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
    • C07D249/06—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles with aryl radicals directly attached to ring atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • C07D271/07—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/10—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles
    • C07D271/107—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles with two aryl or substituted aryl radicals attached in positions 2 and 5
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/06—1,2,3-Thiadiazoles; Hydrogenated 1,2,3-thiadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/08—1,2,4-Thiadiazoles; Hydrogenated 1,2,4-thiadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/12—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
OA60277A 1991-09-18 1992-09-17 Benzanilide derivatives OA10049A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB919119931A GB9119931D0 (en) 1991-09-18 1991-09-18 Chemical compounds
GB929205338A GB9205338D0 (en) 1992-03-12 1992-03-12 Chemical compounds

Publications (1)

Publication Number Publication Date
OA10049A true OA10049A (en) 1996-10-14

Family

ID=26299553

Family Applications (1)

Application Number Title Priority Date Filing Date
OA60277A OA10049A (en) 1991-09-18 1992-09-17 Benzanilide derivatives

Country Status (26)

Country Link
US (2) US5340810A (es)
EP (1) EP0533268B1 (es)
JP (1) JP3295143B2 (es)
KR (1) KR930006011A (es)
CN (1) CN1071919A (es)
AP (1) AP303A (es)
AT (1) ATE204262T1 (es)
AU (1) AU656021B2 (es)
CA (1) CA2078505A1 (es)
CZ (1) CZ285492A3 (es)
DE (1) DE69232003T2 (es)
DK (1) DK0533268T3 (es)
ES (1) ES2162792T3 (es)
FI (1) FI924160A (es)
HU (1) HUT65608A (es)
IL (1) IL103198A (es)
IS (1) IS1618B (es)
MX (1) MX9205280A (es)
MY (1) MY130233A (es)
NO (1) NO923618L (es)
NZ (1) NZ244373A (es)
OA (1) OA10049A (es)
PL (1) PL295960A1 (es)
PT (1) PT533268E (es)
RU (1) RU2077535C1 (es)
TW (1) TW224097B (es)

Families Citing this family (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW240217B (es) * 1992-12-30 1995-02-11 Glaxo Group Ltd
WO1995004729A1 (en) * 1993-08-06 1995-02-16 Smithkline Beecham Plc Amide derivatives as 5ht1d receptor antagonists
WO1995006044A1 (en) * 1993-08-20 1995-03-02 Smithkline Beecham Plc Amide and urea derivatives as 5ht1d receptor antagonists
DE69417427T2 (de) * 1993-09-03 1999-11-25 Smithkline Beecham P.L.C., Brentford Indol- und indolin-derivate als 5ht1d rezeptor antagonisten
EP0716656A1 (en) * 1993-09-03 1996-06-19 Smithkline Beecham Plc Amide derivatives as 5ht1d receptor antagonists
EP0724580A1 (en) * 1993-10-19 1996-08-07 Smithkline Beecham Plc Benzanilide derivatives as 5ht-1d receptor antagonists
EP0733048A1 (en) * 1993-12-07 1996-09-25 Smithkline Beecham Plc Heterocyclic biphenylylamides useful as 5ht1d antagonists
US20020086053A1 (en) * 1993-12-15 2002-07-04 Smithkline Beecham Plc Formulations, tablets of paroxetine and process to prepare them
JPH09506885A (ja) * 1993-12-21 1997-07-08 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー ５ｈｔ▲下１ｄ▼（抗うつ作用）活性を有するインドール、インドリンおよびキノリン誘導体
GB9326008D0 (en) * 1993-12-21 1994-02-23 Smithkline Beecham Plc Novel compounds
JPH09512804A (ja) * 1994-05-06 1997-12-22 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー ５−ｈｔ１ｄアンタゴニストとして有用なビフェニルカルボキシアミド類
EP0763034A1 (en) * 1994-05-28 1997-03-19 Smithkline Beecham Plc Amide derivatives having 5ht1d-antagonist activity
FR2722788B1 (fr) * 1994-07-20 1996-10-04 Pf Medicament Nouvelles piperazides derivees d'aryl piperazine, leurs procedes de preparation, leur utilisation a titre de medicament et les compositions pharmaceutiques les comprenant
US5597826A (en) 1994-09-14 1997-01-28 Pfizer Inc. Compositions containing sertraline and a 5-HT1D receptor agonist or antagonist
US5527920A (en) * 1994-11-18 1996-06-18 Singh; Inder P. Economical manufacturing process for 1,2,3-triazoles
BR9510419A (pt) 1994-12-22 1998-05-19 Smithkline Beecham Plc Compostos espiro tetracíclicos processo para sua preparação e seu uso como antagonistas de receptor de 5ht1d
GB9507203D0 (en) * 1995-04-07 1995-05-31 Smithkline Beecham Plc Novel compounds
FR2740134B1 (fr) * 1995-10-18 1998-01-09 Pf Medicament Derives d'amines cycliques d'aryl-piperazines, leur preparation et les compositions pharmaceutiques les contenant
JPH11514661A (ja) * 1995-11-08 1999-12-14 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー ５ｍｔレセプターアンタゴニストとしてのスピロピペリジン誘導体
US5670526A (en) * 1995-12-21 1997-09-23 Otsuka Pharmaceutical Co., Ltd. 1,3,4-oxadiazoles
FR2744450A1 (fr) * 1996-02-02 1997-08-08 Pf Medicament Nouvelles naphtylpiperazines derivees de cycloazanes substitues, ainsi que leur procede de preparation, les compositions pharmaceutiques et leur utilisation comme medicaments
FR2744449B1 (fr) * 1996-02-02 1998-04-24 Pf Medicament Nouvelles piperazines aromatiques derivees de cycloazanes substitues, ainsi que leur procede de preparation, les compositions pharmaceutiques et leur utilisation comme medicaments
GB9605883D0 (en) * 1996-03-20 1996-05-22 Smithkline Beecham Plc Novel compounds
GB9605945D0 (en) * 1996-03-21 1996-05-22 Smithkline Beecham Plc Novel compounds
SE9601110D0 (sv) 1996-03-22 1996-03-22 Astra Ab Substituted 1,2,3,4-tetrahydronaphthalene derivatives
SK131498A3 (en) 1996-03-29 2000-09-12 Pfizer BENZYL(IDENE)-LACTAM DERIVATIVES, THEIR PREPARATION AND THEIR USEì (54) AS SELECTIVE (ANT)AGONISTS OF 5-HT1A- AND/OR 5-HT1D
US6156783A (en) * 1996-04-30 2000-12-05 Smithkline Beecham P.L.C. Spiroazabicyclic compounds, processes for their preparation, and their pharmaceutical use
FR2761064B1 (fr) * 1997-03-20 1999-06-04 Pf Medicament Piperazines derivees d'amines cycliques, leur preparation et leur application comme medicaments
KR20010006487A (ko) * 1997-04-18 2001-01-26 피터 기딩스 조합된 5ｈｔ1ａ, 5ｈｔ1ｂ 및 5ｈｔ1ｄ 수용체 길항 활성을 갖는 인돌 유도체
SE9900190D0 (sv) 1999-01-22 1999-01-22 Astra Ab New compounds
SE9702799D0 (sv) 1997-07-25 1997-07-25 Astra Ab New compounds
CA2299286A1 (en) * 1997-08-09 1999-02-18 Laramie Mary Gaster Bicyclic compounds as ligands for 5-ht1 receptors
SE9703376D0 (sv) * 1997-09-18 1997-09-18 Astra Ab A new combination
SE9703375D0 (sv) * 1997-09-18 1997-09-18 Astra Ab A new combination
JP2002521377A (ja) * 1998-07-20 2002-07-16 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング ビフェニル誘導体
GB9826412D0 (en) * 1998-12-03 1999-01-27 Glaxo Group Ltd Chemical compounds
CA2385737A1 (en) * 1999-09-25 2001-04-05 Howard Marshall Piperazine derivatives as 5-ht1b antagonists
SE9904723D0 (sv) 1999-12-22 1999-12-22 Carlsson A Research Ab New modulators of dopamine neurotransmission II
SE9904724D0 (sv) 1999-12-22 1999-12-22 Carlsson A Research Ab New modulators of dopamine neurotransmission I
USRE46117E1 (en) 1999-12-22 2016-08-23 Teva Pharmaceuticals International Gmbh Modulators of dopamine neurotransmission
PE20020506A1 (es) 2000-08-22 2002-07-09 Glaxo Group Ltd Derivados de pirazol fusionados como inhibidores de la proteina cinasa
US6514482B1 (en) * 2000-09-19 2003-02-04 Advanced Inhalation Research, Inc. Pulmonary delivery in treating disorders of the central nervous system
US6613308B2 (en) * 2000-09-19 2003-09-02 Advanced Inhalation Research, Inc. Pulmonary delivery in treating disorders of the central nervous system
AU2002230411A1 (en) * 2000-11-29 2002-06-11 Eli Lilly And Company 1-(2-m-methanesulfonamidophenylethyl)-4-(m-trifluoromethylphenyl)piperazine and pharmaceutically acceptable salts and solvates thereof and their use in the treatment of incontinence
AU2002327627B2 (en) 2001-09-14 2006-09-14 Methylgene Inc. Inhibitors of histone deacetylase
GB0124934D0 (en) 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
GB0124938D0 (en) 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
GB0124939D0 (en) 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
GB0124931D0 (en) 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
GB0124936D0 (en) * 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
GB0124932D0 (en) * 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
GB0124933D0 (en) 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
GB0124941D0 (en) 2001-10-17 2001-12-05 Glaxo Group Ltd Chemical compounds
ATE375980T1 (de) 2002-02-12 2007-11-15 Smithkline Beecham Corp Nicotinamide und deren verwendung als p38 inhibitoren
CA2478980C (en) * 2002-03-20 2008-07-15 Advanced Inhalation Research, Inc. Pulmonary delivery for levodopa
US6930137B2 (en) * 2002-05-31 2005-08-16 Fina Technology, Inc. Method of improving blown film processing performance and physical properties
GB0217757D0 (en) 2002-07-31 2002-09-11 Glaxo Group Ltd Novel compounds
SE0203778D0 (sv) * 2002-12-09 2002-12-09 Astrazeneca Ab A new oral immediated release dosage form
US7319111B2 (en) 2003-02-20 2008-01-15 Encysive Pharmaceuticals, Inc. Phenylenediamine Urotensin-II receptor antagonists and CCR-9 antagonists
US7288538B2 (en) 2003-02-20 2007-10-30 Encysive Pharmaceuticals, Inc. Phenylenediamine urotensin-II receptor antagonists and CCR-9 antagonists
GB0308186D0 (en) 2003-04-09 2003-05-14 Smithkline Beecham Corp Novel compounds
GB0308185D0 (en) 2003-04-09 2003-05-14 Smithkline Beecham Corp Novel compounds
GB0308201D0 (en) 2003-04-09 2003-05-14 Smithkline Beecham Corp Novel compounds
GB0318814D0 (en) 2003-08-11 2003-09-10 Smithkline Beecham Corp Novel compounds
AU2003304416A1 (en) * 2003-08-13 2005-03-07 Bf Research Institute, Inc. Probe for disease with amyloid deposit, amyloid-staining agent, remedy and preventive for disease with amyloid deposit and diagnostic probe and staining agent for neurofibril change
ATE473967T1 (de) * 2003-11-26 2010-07-15 Pfizer Prod Inc Aminopyrazolderivate als gsk-3-inhibitoren
US20050215551A1 (en) * 2004-03-25 2005-09-29 Solvay Pharmaceuticals B.V. 1-[2H-1-benzopyran-2-one-8-yl]- piperazine derivatives for the treatment of movement disorders
AR049478A1 (es) 2004-03-25 2006-08-09 Solvay Pharm Bv Un procedimiento para la preparacion de 3-amino-8-(1-piperazinil)-2h-1-benzopiran-2-ona. sales e hidratos y composiciones farmaceuticas.
US7851629B2 (en) 2004-06-08 2010-12-14 Nsab, Filial Af Neurosearch Sweden Ab, Sverige Disubstituted phenylpiperidines as modulators of dopamine and serotonin neurotransmission
DE602005021641D1 (de) 2004-06-08 2010-07-15 Nsab, Filial Af Neurosearch Sweden Ab Neue disubstituierte phenylpiperidine und piperazine als modulatoren der dopamin-neurotransmission
WO2006040155A1 (en) 2004-10-13 2006-04-20 Neurosearch Sweden Ab Process for the synthesis of 4-(3-methanesulfonylphenyl)-1-n-propyl-piperidine
SE529246C2 (sv) 2005-10-13 2007-06-12 Neurosearch Sweden Ab Nya disubstituerade fenyl-piperidiner som modulatorer för dopaminneurotransmission
WO2007077457A2 (en) * 2006-01-06 2007-07-12 The Royal Veterinary College Treatment of equine laminitis with 5-ht1b/ 1d antagonists
EP1921072A1 (en) * 2006-11-10 2008-05-14 Laboratorios del Dr. Esteve S.A. 1,2,3-Triazole derivatives as cannabinoid-receptor modulators
AU2011280890B2 (en) 2010-07-23 2014-07-31 The Board Of Trustees Of The University Of Illinois Apparatus and methods for the automated synthesis of small molecules
CN103429235A (zh) * 2010-12-15 2013-12-04 赖鸿政 用于治疗癌症的化合物及其应用
CA2821900C (en) 2010-12-17 2015-12-08 Mitsubishi Tanabe Pharma Corporation Continuous arycyclic compound
EP2787997A4 (en) 2011-12-08 2015-05-27 Ivax Int Gmbh HYDROBROMIDE SALT OF PRIDOPIDINE
ES2776678T3 (es) 2012-04-04 2020-07-31 Prilenia Neurotherapeutics Ltd Composiciones farmacéuticas para terapia de combinación
JP5977349B2 (ja) * 2012-06-15 2016-08-24 田辺三菱製薬株式会社 芳香族複素環化合物
WO2020183011A1 (en) 2019-03-14 2020-09-17 Institut Curie Htr1d inhibitors and uses thereof in the treatment of cancer
WO2023205475A1 (en) * 2022-04-21 2023-10-26 Nimbus Clotho, Inc. Ctps1 inhibitors and uses thereof

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3192213A (en) * 1962-10-12 1965-06-29 Olin Mathieson Aminoalkyl anilides
DE1668723A1 (de) * 1966-09-16 1971-04-08 Toyo Jozo Kk Verfahren zum Herstellen von Verbindungen mit Saeureamid-Bindung
AU499714B2 (en) * 1974-10-14 1979-05-03 Chugai Seiyaku Kabushiki Kaisha Bis(benzamido)-benzene derivatives & process for preparing thesame
US4058523A (en) * 1974-10-14 1977-11-15 Chugai Seiyaku Kabushiki Kaisha Bis(benzamido)-benzene derivatives
US4013647A (en) * 1976-03-23 1977-03-22 American Home Products Corporation Morpholine containing tetrazole-5-carboxamide derivatives
DE3005287A1 (de) * 1980-02-13 1981-08-20 Basf Ag, 6700 Ludwigshafen Phenylpiperazinderivate von 1,3,4-oxadiazolylphenolen, ihre herstellung und diese enthaltende therapeutische mittel
US4735959A (en) * 1981-01-10 1988-04-05 Dr. Karl Thomae Gmbh Carboxylic acid amides and pharmaceutical compositions containing them
DE3100575A1 (de) * 1981-01-10 1982-09-02 Dr. Karl Thomae Gmbh, 7950 Biberach "neue benzoesaeuren, ihre herstellung und ihre verwendung als arzneimittel"
US4562201A (en) * 1982-07-26 1985-12-31 American Hospital Supply Corporation Aminomethyl benzanilides
US4579866A (en) * 1984-05-29 1986-04-01 Usv Pharmaceutical Corp. Phenylacetamides as anti-allergy, anti-asthma and anti-inflammatory agents
US4778796A (en) * 1985-07-19 1988-10-18 Dainippon Pharmaceutical Co., Ltd. ω-(3-pyridyl)alkenamide derivatives and anti-allergenic pharmaceutical compositions containing same
DE3600288A1 (de) * 1986-01-08 1987-07-16 Bayer Ag Verwendung von amiden zur verbesserung der kulturpflanzen-vertraeglichkeit von herbizid wirksamen sulfonylharnstoff-derivaten
CA1334092C (en) * 1986-07-11 1995-01-24 David John Carini Angiotensin ii receptor blocking imidazoles
US4853398A (en) * 1987-04-13 1989-08-01 Eli Lilly And Company Leukotriene antagonists and use thereas
US4826990A (en) * 1987-09-30 1989-05-02 American Home Products Corporation 2-aryl substituted heterocyclic compounds as antiallergic and antiinflammatory agents
ZA89135B (en) * 1988-01-11 1989-10-25 Duphar Int Res Method of treating hematologic diseases and pharmaceutical composition to be used therefor
DE3810848A1 (de) * 1988-03-30 1989-10-19 Boehringer Ingelheim Kg Neue 2,3,4-substituierte imidazole und 3,4,5-substituierte 1,2,4-triazole, ihre herstellung und verwendung
ATE81651T1 (de) * 1988-10-10 1992-11-15 Akzo Nv Substituierte aromatische verbindungen mit zentraler nervensystem-wirkung.

Also Published As

Publication number Publication date
NO923618L (no) 1993-03-19
NZ244373A (en) 1995-03-28
NO923618D0 (no) 1992-09-17
RU2077535C1 (ru) 1997-04-20
EP0533268B1 (en) 2001-08-16
JPH06116251A (ja) 1994-04-26
HUT65608A (en) 1994-07-28
US5510350A (en) 1996-04-23
CN1071919A (zh) 1993-05-12
JP3295143B2 (ja) 2002-06-24
IS3915A (is) 1993-03-19
AP303A (en) 1994-01-28
CZ285492A3 (en) 1993-04-14
ATE204262T1 (de) 2001-09-15
HU9202968D0 (en) 1992-12-28
MY130233A (en) 2007-06-29
EP0533268A1 (en) 1993-03-24
US5340810A (en) 1994-08-23
FI924160A0 (fi) 1992-09-17
PL295960A1 (en) 1993-09-06
IS1618B (is) 1996-10-18
MX9205280A (es) 1993-03-01
TW224097B (es) 1994-05-21
PT533268E (pt) 2002-02-28
KR930006011A (ko) 1993-04-20
AU656021B2 (en) 1995-01-19
IL103198A0 (en) 1993-02-21
AP9200427A0 (en) 1992-10-31
DE69232003T2 (de) 2002-04-25
CA2078505A1 (en) 1993-03-19
DE69232003D1 (de) 2001-09-20
FI924160A (fi) 1993-03-19
ES2162792T3 (es) 2002-01-16
DK0533268T3 (da) 2001-12-03
IL103198A (en) 1996-06-18
AU2453092A (en) 1993-03-25

Similar Documents

Publication Publication Date Title
OA10049A (en) Benzanilide derivatives
US5356893A (en) Benzanilide derivatives
WO1994015920A1 (en) Benzanilide derivatives as 5-ht1d-antagonists
US5358948A (en) Benzanilide derivatives
WO2020088357A1 (zh) 联苯类化合物、其中间体、制备方法、药物组合物及应用
GB2273930A (en) Benzanilide derivatives
GB2276162A (en) Aniline and benazilide derivatives
JPH06505239A (ja) 抗炎症剤として有用な４，６−ジ−第三ブチル−５−ヒドロキシ−１，３−ピリミジンの置換されたヘテロアリール類似体
CA2515847A1 (en) Heterocyclic compounds useful as nurr-1 activators
JP2005526024A (ja) インスリン分泌を阻害するための化合物及びそれに関連する方法
JPH04234860A (ja) チアジン（又はオキサジン）誘導体、その製法及びその合成中間体
EP2252599A1 (en) Triazole amide derivatives for use in therapy
WO2011151361A1 (en) Novel compounds
FI63394C (fi) Analogifoerfarande foer framstaellning av kemoterapeutiskt anvaendbara heteroarylfoereningar
EP0767782B1 (en) Aryl and heteroaryl alkoxynaphthalene derivatives
EP2238131A1 (en) 5-o-substituted 3-n-phenyl-1,3,4-oxadiazolones for medical use
CA1163267A (en) Isoxazolyl indolamines
US3699116A (en) 2,2'-azines of 2,4-thiazolidinediones
GB2276164A (en) Aniline and benzanilide derivatives
WO2010074587A2 (en) 5-o-substituted 3-n-aryl-1,3,4-oxadiazolones for medical use
WO2009087218A1 (en) Thiazoltriazoles and thiazolimidazoles as antagonists of the mglur5 receptor
US3308119A (en) Sulfanilamides
US3121095A (en) alpha-enolacylates of beta-acyl-gamma-phenyl-alpha-tetronic acids
CA1081236A (en) Process for the production of novel triazole derivates
SE447112B (sv) Mellanprodukter for framstellning av 4-hydroxi-3-(5-metyl-3-isoxazolylkarbamoyl)-2-metyl-2h-1,2-bensotiazin-1,1-dioxid med anti-inflammatorisk aktivitet